108 related articles for article (PubMed ID: 21557977)
61. Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.
Maekawa R; Matsumoto M; Kitagawa T; Harada M; Sato K
Cancer Immunol Immunother; 1986; 23(1):25-30. PubMed ID: 3490306
[TBL] [Abstract][Full Text] [Related]
62. Vaccine leads to memory loss.
Haanen JB; Schumacher TN
Nat Med; 2007 Mar; 13(3):248-50. PubMed ID: 17342116
[No Abstract] [Full Text] [Related]
63. Tumor nano-lysate activates dendritic cells to evoke a preventative immune response.
Dombroski JA; Fabiano AR; Knoblauch SV; Rowland SJ; Gibson-Corley KN; King MR
J Immunol Methods; 2024 Jan; 524():113601. PubMed ID: 38092224
[TBL] [Abstract][Full Text] [Related]
64. Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model.
Yazdi MH; Mahdavi M; Faghfuri E; Faramarzi MA; Sepehrizadeh Z; Hassan ZM; Gholami M; Shahverdi AR
Iran J Biotechnol; 2015 Jun; 13(2):1-9. PubMed ID: 28959284
[TBL] [Abstract][Full Text] [Related]
65. ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Xu J; Su SM; Zhang X; Chan UI; Adhav R; Shu X; Liu J; Li J; Mo L; Wang Y; An T; Lei JH; Miao K; Deng CX; Xu X
J Clin Invest; 2022 Mar; 132(5):. PubMed ID: 35025764
[TBL] [Abstract][Full Text] [Related]
66. Does memantine show chemopreventive effect against mice 4T1 breast tumor model?
Albayrak G; Bali EB; Korkmaz FD; Bağrıaçık EÜ
Turk J Med Sci; 2022 Jun; 52(3):841-847. PubMed ID: 36326318
[TBL] [Abstract][Full Text] [Related]
67. Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model.
Zare H; Bakherad H; Nasr Esfahani A; Norouzi M; Aghamollaei H; Mousavi Gargari SL; Mahmoodi F; Aliomrani M; Ebrahimizadeh W
Bioimpacts; 2024; 14(2):27829. PubMed ID: 38505675
[TBL] [Abstract][Full Text] [Related]
68. Nanopulse Stimulation (NPS) Induces Tumor Ablation and Immunity in Orthotopic 4T1 Mouse Breast Cancer: A Review.
Beebe SJ; Lassiter BP; Guo S
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29601471
[TBL] [Abstract][Full Text] [Related]
69. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.
Orecchia P; Balza E; Pietra G; Conte R; Bizzarri N; Ferrero S; Mingari MC; Carnemolla B
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443604
[TBL] [Abstract][Full Text] [Related]
70. Measuring response to therapy by near-infrared imaging of tumors using a phosphatidylserine-targeting antibody fragment.
Gong J; Archer R; Brown M; Fisher S; Chang C; Peacock M; Hughes C; Freimark B
Mol Imaging; 2013 Jun; 12(4):244-56. PubMed ID: 23651502
[TBL] [Abstract][Full Text] [Related]
71. Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.
Belzile O; Huang X; Gong J; Carlson J; Schroit AJ; Brekken RA; Freimark BD
Immunotargets Ther; 2018; 7():1-14. PubMed ID: 29417044
[TBL] [Abstract][Full Text] [Related]
72. Passage Number of 4T1 Cells Influences the Development of Tumour and the Progression of Metastasis in 4T1 Orthotopic Mice.
Rajaratinam H; Rasudin NS; Safuan S; Abdullah NA; Mokhtar NF; Mohd Fuad WE
Malays J Med Sci; 2022 Jun; 29(3):30-42. PubMed ID: 35846500
[TBL] [Abstract][Full Text] [Related]
73. Engineering a Next-Gen IL2 Therapy.
Cancer Discov; 2021 Jun; 11(6):1312-1313. PubMed ID: 33931435
[TBL] [Abstract][Full Text] [Related]
74. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
75. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation.
Yin Y; Huang X; Lynn KD; Thorpe PE
Cancer Immunol Res; 2013 Oct; 1(4):256-68. PubMed ID: 24777853
[TBL] [Abstract][Full Text] [Related]
76. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice.
Zhang L; Zhou H; Belzile O; Thorpe P; Zhao D
J Control Release; 2014 Jun; 183():114-23. PubMed ID: 24698945
[TBL] [Abstract][Full Text] [Related]
77. MHY1485 potentiates immunogenic cell death induction and anti-cancer immunity following irradiation.
Sun L; Morikawa K; Sogo Y; Sugiura Y
J Radiat Res; 2024 Mar; 65(2):205-214. PubMed ID: 38330507
[TBL] [Abstract][Full Text] [Related]
78. Interleukin 2-Based Fusion Proteins for the Treatment of Cancer.
MacDonald A; Wu TC; Hung CF
J Immunol Res; 2021; 2021():7855808. PubMed ID: 34790830
[TBL] [Abstract][Full Text] [Related]
79. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.
Bou-Dargham MJ; Draughon S; Cantrell V; Khamis ZI; Sang QA
J Cancer; 2021; 12(23):6949-6963. PubMed ID: 34729098
[TBL] [Abstract][Full Text] [Related]
80. Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.
Zhao Y; Zheng X; Zheng Y; Chen Y; Fei W; Wang F; Zheng C
Front Oncol; 2021; 11():650453. PubMed ID: 33968752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
